182 related articles for article (PubMed ID: 25521244)
1. Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro.
Weiss J; Theile D; Dvorak Z; Haefeli WE
Pharmaceutics; 2014 Dec; 6(4):632-50. PubMed ID: 25521244
[TBL] [Abstract][Full Text] [Related]
2. Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro.
Weiss J; Haefeli WE
Int J Antimicrob Agents; 2013 May; 41(5):484-7. PubMed ID: 23428312
[TBL] [Abstract][Full Text] [Related]
3. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.
Theile D; Allendorf D; Köhler BC; Jassowicz A; Weiss J
J Pharm Pharmacol; 2015 Nov; 67(11):1575-84. PubMed ID: 26255619
[TBL] [Abstract][Full Text] [Related]
4. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.
Weiss J; Haefeli WE
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1093-8. PubMed ID: 21805352
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions.
Weiss J; Gajek T; Köhler BC; Haefeli WE
Pharmaceutics; 2016 Feb; 8(1):. PubMed ID: 26927160
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro.
Rickert V; Haefeli WE; Weiss J
Pulm Pharmacol Ther; 2014 Aug; 28(2):130-7. PubMed ID: 24657506
[TBL] [Abstract][Full Text] [Related]
7. Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions.
Weiss J; Bajraktari-Sylejmani G; Haefeli WE
Chem Biol Interact; 2021 Apr; 338():109428. PubMed ID: 33647240
[TBL] [Abstract][Full Text] [Related]
8. Interaction of Hydroxychloroquine with Pharmacokinetically Important Drug Transporters.
Weiss J; Bajraktari-Sylejmani G; Haefeli WE
Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 32992777
[TBL] [Abstract][Full Text] [Related]
9. Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro.
Weiss J; Becker JP; Haefeli WE
Int J Antimicrob Agents; 2014 Feb; 43(2):184-8. PubMed ID: 24332840
[TBL] [Abstract][Full Text] [Related]
10. Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro.
Weiss J; Theile D; Rüppell MA; Speck T; Spalwisz A; Haefeli WE
Eur J Pharmacol; 2013 Feb; 701(1-3):168-75. PubMed ID: 23353592
[TBL] [Abstract][Full Text] [Related]
11. Drug-drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro.
Blank A; Meier K; Urban S; Haefeli WE; Weiss J
Antivir Ther; 2018; 23(3):267-275. PubMed ID: 29134945
[TBL] [Abstract][Full Text] [Related]
12. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.
Theile D; Haefeli WE; Weiss J
Endocrine; 2015 Aug; 49(3):842-53. PubMed ID: 25542188
[TBL] [Abstract][Full Text] [Related]
13. Desmethyl bosentan displays a similar in vitro interaction profile as bosentan.
Weiss J; Baumann S; Theile D; Haefeli WE
Pulm Pharmacol Ther; 2015 Feb; 30():80-6. PubMed ID: 25535031
[TBL] [Abstract][Full Text] [Related]
14. Impact of enzalutamide and its main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters.
Weiss J; Kocher J; Mueller C; Rosenzweig S; Theile D
Biopharm Drug Dispos; 2017 Dec; 38(9):517-525. PubMed ID: 28865089
[TBL] [Abstract][Full Text] [Related]
15. Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes.
Dunkoksung W; Vardhanabhuti N; Siripong P; Jianmongkol S
Drug Metab Dispos; 2019 Oct; 47(10):1040-1049. PubMed ID: 31399508
[TBL] [Abstract][Full Text] [Related]
16. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
17. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract][Full Text] [Related]
18. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
Weiss J; Sauer A; Divac N; Herzog M; Schwedhelm E; Böger RH; Haefeli WE; Benndorf RA
Biopharm Drug Dispos; 2010 Mar; 31(2-3):150-61. PubMed ID: 20222053
[TBL] [Abstract][Full Text] [Related]
19. An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides.
Kazmi F; Yerino P; McCoy C; Parkinson A; Buckley DB; Ogilvie BW
Drug Metab Dispos; 2018 Aug; 46(8):1066-1074. PubMed ID: 29735754
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
